Various treatment modalities have been described for retinal capillary hemangioma. Our purpose is to present a case of juxtapapillary retinal capillary hemangioma treated with photodynamic therapy. A 69-year-old woman with no previous ocular history presented with blurred vision and photopsias in the right eye three months ago. At presentation, her best corrected visual acuity was 6/9 in the right eye and 6/6 in the left eye. The anterior segment was totally normal and IOP was normal in both eyes as well. Dilated fundoscopy revealed a yellowish, well-circumscribed, elevated area with blood vessels, on the inferior margin of the right optic disc, as optic disc edema. Fluorescein angiography and angiogram with indocyanine green confirmed the diagnosis of juxtapapillary retinal capillary hemangioma. The patient was treated with photodynamic therapy with verteporfin and three months later her visual acuity was 6/7.5 in the right eye, while the lesion was slightly smaller. These findings remained stable at the one-year follow-up. In conclusion, photodynamic therapy offers promising anatomical and functional results for juxtapapillary retinal capillary hemangioma, providing visual acuity improvement or even stabilization and restriction of enlargement of the lesion. 1. Introduction Retinal capillary hemangioma (RCH) or hemangioblastoma is an uncommon benign vascular tumor and may occur sporadically (54%) or as a manifestation of von Hippel-Lindau (VHL) disease (46%) [1–4]. Although it is usually considered as a solitary unilateral tumor, when associated with VHL disease, up to 50% of the cases present multifocal or bilateral involvement [1–8]. The clinical course of the disease is usually progressive and difficult to predict [7, 8]. As the RCH enlarges, it can cause complications, such as exudation, subretinal fluid accumulation, macular edema, and exudative retinal detachment, resulting in visual deterioration. Furthermore, glial proliferation can lead to epiretinal membrane development or tractional retinal detachment [1–8]. RCH can be located at the disc (papillary), juxtapapillary, or at the peripheral retina, occurring most commonly at the temporal side of the disc [1–8]. Treatment depends on the location and size of the RCH and varies from observation to radiotherapy, cryotherapy, transpupillary thermotherapy, laser photocoagulation, photodynamic treatment (PDT), antivascular endothelial growth factor (anti-VEGF) agents, intravitreal triamcinolone, vitreoretinal surgery, or combination of treatment modalities [5, 6, 9–28]. There are few case reports and
References
[1]
A. D. Singh, M. Nouri, C. L. Shields, J. A. Shields, and A. F. Smith, “Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel-Lindau disease,” Ophthalmology, vol. 108, no. 10, pp. 1907–1911, 2001.
[2]
M. A. Magee, A. J. Kroll, P. L. Lou, and E. A. Ryan, “Retinal capillary hemangiomas and von Hippel-Lindau disease,” Seminars in Ophthalmology, vol. 21, no. 3, pp. 143–150, 2006.
[3]
R. F. Schindler, L. K. Sarin, and P. R. MacDonald, “Hemangiomas of the optic disc,” Canadian Journal of Ophthalmology, vol. 10, no. 3, pp. 305–318, 1975.
[4]
J. D. Gass and R. Braunstein, “Sessile and exophytic capillary angiomas of the juxtapapillary retina and optic nerve head,” Archives of Ophthalmology, vol. 98, no. 10, pp. 1790–1797, 1980.
[5]
R. Sachdeva, H. Dadgostar, P. K. Kaiser, J. E. Sears, and A. D. Singh, “Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma,” Acta Ophthalmologica, vol. 88, no. 8, pp. e334–e340, 2010.
[6]
J. R. Golshevsky and J. O'Day, “Photodynamic therapy in the management of juxtapapillary capillary haemangiomas,” Clinical and Experimental Ophthalmology, vol. 33, no. 5, pp. 509–512, 2005.
[7]
C. M. McCabe, H. W. Flynn Jr., C. L. Shields, et al., “Juxtapapillary capillary hemangiomas: clinical features and visual acuity outcomes,” Ophthalmology, vol. 107, no. 12, pp. 2240–2248, 2000.
[8]
M.-T. Kuo, H.-K. Kou, M.-L. Kao, M.-H. Tsai, Y.-J. Chen, and S.-A. Lin, “Retinal capillary hemangiomas: clinical manifestations and visual prognosis,” Chang Gung Medical Journal, vol. 25, no. 10, pp. 672–682, 2002.
[9]
H. R. McDonald, “Diagnostic and therapeutic challenges. Juxtapapillary retina capillary hemangioma,” Retina, vol. 23, no. 1, pp. 86–91, 2003.
[10]
S. A. Milewski, “Spontaneous regression of a capillary hemangioma of the optic disc,” Archives of Ophthalmology, vol. 120, no. 8, pp. 1100–1101, 2002.
[11]
M. C. Molina, J. D. Paulo, and J. H. Donado, “Spontaneous regression of a retinal capillary hemangioma,” Retina, vol. 28, no. 10, pp. 1554–1555, 2008.
[12]
V. Russo, A. Stella, A. Barone, I. U. Scott, and N. D. Noci, “Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma,” International Ophthalmology, vol. 32, no. 1, pp. 71–75, 2012.
[13]
J. Cheung, G. K. Lee, and C. C. Tham, “A large retinal capillary hemangioma in the anterior retina treated with photodynamic therapy,” Case Reports in Ophthalmology, vol. 3, pp. 1–4, 2012.
[14]
T. Ach, D. Thiemeyer, A. E. Hoeh, K. B. Schaal, and S. Dithmar, “Intravitreal bevacizumab for retinal capillary haemangioma: longterm results,” Acta Ophthalmologica, vol. 88, no. 4, pp. e137–e138, 2010.
[15]
S. S. Dahr, M. Cusick, H. Rodriguez-Coleman et al., “Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina,” Retina, vol. 27, no. 2, pp. 150–158, 2007.
[16]
E. Chelala, A. Dirani, and A. Fadlallah, “Intravitreal anti-VEGF injection for the treatment of progressive juxtapapillary retinal capillary hemangioma: a case report and mini review of the literature,” Journal of Clinical Ophthalmology, vol. 7, pp. 2143–2146, 2013.
[17]
A. H. C. Fong, K. K. W. Li, and D. Wong, “Intravitreal ranibizumab, photodynamic therapy, and vitreous surgery for the treatment of juxtapapillary retinal capillary hemangioma,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 4, pp. 625–627, 2011.
[18]
S. Mennel, C. H. Meyer, and J. Callizo, “Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma,” Acta Ophthalmologica, vol. 88, no. 5, pp. 610–613, 2010.
[19]
F. Ziemssen, M. Voelker, W. Inhoffen, K. U. Bartz-Schmidt, and F. Gelisken, “Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy,” Eye, vol. 21, no. 8, pp. 1125–1126, 2007.
[20]
L. Wittenberg and P. Ma, “Treatment of a von Hippel-Lindau retinal capillary hemangioma with photodynamic therapy,” Canadian Journal of Ophthalmology, vol. 43, no. 5, pp. 605–606, 2008.
[21]
V. P. Papastefanou, S. Pilli, A. Stinghe, A. J. Lotery, and V. M. Cohen, “Photodynamic therapy for retinal capillary hemangioma,” Eye, vol. 27, pp. 438–442, 2013.
[22]
S. J. Bakri, J. E. Sears, and A. D. Singh, “Transient closure of a retinal capillary hemangioma with verteporfin photodynamic therapy,” Retina, vol. 25, no. 8, pp. 1103–1104, 2005.
[23]
T. M. Aaberg Jr., T. M. Aaberg Sr., D. F. Martin, J. P. Gilman, and R. Myles, “Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy,” Archives of Ophthalmology, vol. 123, no. 3, pp. 328–332, 2005.
[24]
N. H. Atebara, “Retinal capillary hemangioma treated with verteporfin photodynamic therapy,” The American Journal of Ophthalmology, vol. 134, no. 5, pp. 788–790, 2002.
[25]
N. Toyokawa, H. Kimura, and S. Kuroda, “Juxtapapillary capillary hemangioma treated by intravitreal injection of bevacizumab combined with posterior subtenon injection of triamcinolone acetonide,” Japanese Journal of Ophthalmology, vol. 54, no. 2, pp. 168–170, 2010.
[26]
U. M. Schmidt-Erfurth, C. Kusserow, I. A. Barbazetto, and H. Laqua, “Benefits and complications of photodynamic therapy of papillary capillary hemangiomas,” Ophthalmology, vol. 109, no. 7, pp. 1256–1266, 2002.
[27]
T. Baba, M. Kitahashi, M. Kubota-Taniai, T. Oshitari, and S. Yamamoto, “Subretinal hemorrhage after photodynamic therapy for juxtapapillary retinal capillary hemangioma,” Case Reports in Ophthalmology, vol. 2, no. 1, pp. 134–139, 2011.
[28]
A. D. Singh, M. Nouri, C. L. Shields, J. A. Shields, and N. Perez, “Treatment of retinal capillary hemangioma,” Ophthalmology, vol. 109, no. 10, pp. 1799–1806, 2002.
[29]
P. K. Kaiser, “Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension. TAP report no. 8,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 244, no. 9, pp. 1132–1142, 2006.
[30]
I. Barbazetto and U. Schmidt-Erfurth, “Photodynamic therapy of choroidal hemangioma: two case reports,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 238, no. 3, pp. 214–221, 2000.
